Sara Tadesse-Bell, MPH

Director, Patient Centered Outcomes Research
Novo Nordisk
Plainsboro, New Jersey, United States

Disclosure information not submitted.

Presentation(s):

• MON-733 - 3-Month Real-World Weight-Related Outcomes Among Patients Taking Oral Semaglutide 25 mg: Insights From the WeGoTogether Patient Support Solution App

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT